Interleukin-2 targeted fusion toxin using parts of the diphtheria toxin data
SRGN (Hopkinton, Mass.) and collaborators published early results of an ongoing Phase I/II trial showing a marked response
Gathering data...
SRGN (Hopkinton, Mass.) and collaborators published early results of an ongoing Phase I/II trial showing a marked response